Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.77% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.32B.
Undervalued
The company’s latest PE is 16.44, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 270.87M shares, increasing 0.29% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.